Wintac has received an approval for issue of 66.83 lakh equity shares on Rights basis to the existing shareholders of the company in the ratio of 3 : 2 i.e., 2 (two) shares for every 3 (three) shares held at a price of Rs 100 per share (Rs10 face value + Rs 90 premium per share) aggregating to Rs 66.83 crore.
The funds raised would be utilised to meet the capital expenditure on construction of New Manufacturing Facility and other corporate funds requirements and also to augment the long term working capital of the company. The board of directors at their meeting held on July 27, 2017, has approved for the same.
Wintac’s range of specialties includes Antifungal, Anticancer, Cardiovascular, Corticosterid , Antiemetic, Large and small volume injectable and Ophthalmic solutions. The company has also forayed into the field of critical care by manufacturing and marketing products targeted to the critically ill patients.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1530.00 |
Dr. Reddys Lab | 5802.00 |
Cipla | 1399.35 |
Zydus Lifesciences | 1051.90 |
Lupin | 1653.75 |
View more.. |